The company also closed on a $3 million seed funding round with participation from Tedco, Wexford Science and Technology, Riptide Ventures, Gaingels and other investors, according to a March 21 news release from Previse.
Data from the American Cancer Society in 2023 estimates that esophageal cancer has only a 20 percent five-year survival rate. By identifying Barrett’s esophagus, the precursor to esophageal cancer, physicians can improve survival rates, the release said.
Esopredict will allow physicians to provide a tailored approach to Barrett’s esophagus treatment. It can deliver timely and accurate risk predictions over a five-year horizon and identify changes in the DNA levels of four genes using a sample of Barrett’s esophagus cells, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.